These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 34332798)

  • 21. Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study.
    Le TK; Brown I; Goldberg R; Taylor MT; Deng J; Parthasarathy V; Bordeaux ZA; Alphonse MP; Kwatra MM; Naranbhai V; Gusev A; Alhariri J; LeBoeuf NR; Reynolds KL; Cappelli LC; Naidoo J; Brahmer JR; Kang S; Semenov YR; Kwatra SG
    J Invest Dermatol; 2022 Nov; 142(11):2896-2908.e4. PubMed ID: 35605659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How to recognize and manage skin toxicities associated with immune checkpoint inhibitors: a practical approach.
    Kawsar A; Hussain K; Muinonen-Martin AJ; Fearfield L
    Br J Dermatol; 2023 Oct; 189(Suppl 1):i3-i10. PubMed ID: 37903072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes.
    Hashimoto H; Ito T; Ichiki T; Yamada Y; Oda Y; Furue M
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33673164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics, Management, and Prognostic Implications of Adverse Effects of Immune Checkpoint Inhibitors: A Systematic Review.
    Juan-Carpena G; Palazón-Cabanes JC; Blanes-Martínez M
    Actas Dermosifiliogr; 2022 Apr; 113(4):376-387. PubMed ID: 35623728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
    Keiser MF; Patel AB; Altan M
    Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The life-threatening eruptions of immune checkpoint inhibitor therapy.
    Coleman EL; Olamiju B; Leventhal JS
    Clin Dermatol; 2020; 38(1):94-104. PubMed ID: 32197753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
    Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
    J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
    Nadelmann ER; Yeh JE; Chen ST
    JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System.
    Raschi E; Antonazzo IC; La Placa M; Ardizzoni A; Poluzzi E; De Ponti F
    Oncologist; 2019 Nov; 24(11):e1228-e1231. PubMed ID: 31387950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis.
    Curkovic NB; Bai K; Ye F; Johnson DB
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of Dermatologic Toxicities Related to Immune Checkpoint Inhibitors].
    Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):639-644. PubMed ID: 31650946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL; Clarke JM; Morse MA; Shah A; Barrow W; Selim MA; Hall RP; Cardones AR
    Br J Dermatol; 2019 Sep; 181(3):580-583. PubMed ID: 30244487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review].
    Gomes N; Sibaud V; Azevedo F; Magina S
    Acta Med Port; 2020 May; 33(5):335-343. PubMed ID: 32416756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses.
    Le TK; Kaul S; Cappelli LC; Naidoo J; Semenov YR; Kwatra SG
    J Dermatolog Treat; 2022 May; 33(3):1691-1695. PubMed ID: 33656965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies.
    Daher R; Ruplin A; Gupta S; Spiess PE; Kamat AM; Cigliola A; Tateo V; Mercinelli C; Grivas P; Necchi A
    Crit Rev Oncol Hematol; 2024 Aug; 200():104420. PubMed ID: 38906514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dermatologic toxicities of immune checkpoint inhibitors].
    Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
    Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral mucosal toxicities induced by immune checkpoint inhibitors: Clinical features and algorithm management.
    Vigarios E; Sibaud V
    Ann Dermatol Venereol; 2023 Jun; 150(2):83-88. PubMed ID: 36935341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selected cutaneous adverse events in patients treated with ICI monotherapy and combination therapy: a retrospective pharmacovigilance study and meta-analysis.
    Lu W; Zhang H; Guo Q; Gou Z; Yao J
    Front Pharmacol; 2023; 14():1076473. PubMed ID: 37332342
    [No Abstract]   [Full Text] [Related]  

  • 40. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
    Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
    Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.